TY - JOUR
T1 - The STAR*D project results
T2 - A comprehensive review of findings
AU - Warden, Diane
AU - Rush, A. John
AU - Trivedi, Madhukar H.
AU - Fava, Maurizio
AU - Wisniewski, Stephen R.
N1 - Funding Information:
Dr. Rush has served as a consultant for Advanced Neuromodulation Systems, Inc., Best Practice Project Management, Jazz Pharmaceuticals, Inc., Merck & Co., Inc., Neuronetics, Inc., Cyberonics, Inc., Forest Pharmaceuticals, Inc., GlaxoSmithKline, Inc., Pfizer, Inc., and Ono Pharmaceutical Co.; has served as a speaker for Cyberonics, Inc., Forest Pharmaceuticals, Inc., and GlaxoSmithKline, Inc.; has received research support from the National Institute of Mental Health, the Robert Wood Johnson Foundation, and the Stanley Medical Research Institute; and has owned stock in Pfizer, Inc.
Funding Information:
This project has received funding from the National Institute of Mental Health, National Institutes of Health, under contract N01MH90003 to UT South-western Medical Center at Dallas (principal investigator Dr. Rush). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government. The authors wish to acknowledge the editorial support of Jon Kilner and the secretarial support of Fast Word Information Processing, Inc. This work is supported by R01 MH-164062-01A1, Computerized Decision Support System for Depression, awarded through the National Institute of Mental Health (principal investigator Dr. Trivedi) and T32 NIH Training Grant MH067543-04 from the UT Southwestern Mood Disorders Clinical Intervention Training Program.
PY - 2007/12
Y1 - 2007/12
N2 - The Sequenced Treatment Alternatives to Relieve Depression trial enrolled outpatients with nonpsychotic major depressive disorder treated prospectively in a series of randomized controlled trials. These were conducted in representative primary and psychiatric practices. Remission rates for treatment steps 1 to 4 based on the 16-item Quick Inventory of Depressive Symptomatology-Self-report were 37%, 31%, 14%, and 13%, respectively. There were no differences in remission rates or times to remission among medication switch or among medication augmentation strategies at any treatment level. Participants who required increasing numbers of treatment steps showed greater depressive illness burden and increasingly greater relapse rates in the naturalistic follow-up period (40%-71%). Prognosis was better at all levels for participants who entered follow-up in remission as opposed to those who entered with response without remission. These results highlight the prevalence of treatment-resistant depression and suggest potential benefit for using more vigorous treatments in the earlier steps.
AB - The Sequenced Treatment Alternatives to Relieve Depression trial enrolled outpatients with nonpsychotic major depressive disorder treated prospectively in a series of randomized controlled trials. These were conducted in representative primary and psychiatric practices. Remission rates for treatment steps 1 to 4 based on the 16-item Quick Inventory of Depressive Symptomatology-Self-report were 37%, 31%, 14%, and 13%, respectively. There were no differences in remission rates or times to remission among medication switch or among medication augmentation strategies at any treatment level. Participants who required increasing numbers of treatment steps showed greater depressive illness burden and increasingly greater relapse rates in the naturalistic follow-up period (40%-71%). Prognosis was better at all levels for participants who entered follow-up in remission as opposed to those who entered with response without remission. These results highlight the prevalence of treatment-resistant depression and suggest potential benefit for using more vigorous treatments in the earlier steps.
UR - http://www.scopus.com/inward/record.url?scp=37349044684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37349044684&partnerID=8YFLogxK
U2 - 10.1007/s11920-007-0061-3
DO - 10.1007/s11920-007-0061-3
M3 - Review article
C2 - 18221624
AN - SCOPUS:37349044684
SN - 1523-3812
VL - 9
SP - 449
EP - 459
JO - Current psychiatry reports
JF - Current psychiatry reports
IS - 6
ER -